Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

807191

	registered interest
	date	15/12/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Breast Cancer: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, with reference to the commercial agreement announced by NHS England on 9 November 2017, what the timetable is for NICE to issue final guidance on Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and docetaxel for HER2 positive metastatic or locally recurrent unresectable breast cancer.
	tabling member constituency	North Warwickshire
	tabling member printed	Craig Tracey
	uin	119837
	answer	answer is ministerial correction date of answer 22/12/2017 answer text <p>The timetable for the National Institute for Health and Care Excellence’s (NICE) guidance on Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and docetaxel for HER2 positive metastatic or locally recurrent unresectable breast cancer is still to be confirmed. Perjeta remains available to new and existing National Health Service patients through the Cancer Drugs Fund pending NICE’s final guidance.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 22/12/2017 11:38:14 answering member 4067 label Biography information for Steve Brine
	tabling member	4509 label Biography information for Craig Tracey

807179

	registered interest
	date	15/12/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Lumacaftor/ivacaftor: Prescriptions
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how many people with cystic fibrosis have been prescribed Orkambi in (a) England and (b) Wales in each of the last five years.
	tabling member constituency	Ceredigion
	tabling member printed	Ben Lake
	uin	119827
	answer	answer is ministerial correction date of answer 22/12/2017 answer text <p>No prescriptions for Orkambi have been submitted to the NHS Business Services Authority and NHS Digital in each of the last five years in England. We do not hold any data for Wales.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 22/12/2017 13:43:00 answering member 4067 label Biography information for Steve Brine
	tabling member	4630 label Biography information for Ben Lake